Original Research
Published on 12 Feb 2026
First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study
in Health Economics
- 296 views
Original Research
Published on 12 Feb 2026
in Health Economics
Systematic Review
Published on 12 Feb 2026
in Dermatology
Mini Review
Published on 12 Feb 2026
in Rheumatology
Case Report
Published on 12 Feb 2026
in Coronary Artery Disease
Original Research
Published on 12 Feb 2026
in Environmental Health and Exposome
Original Research
Published on 12 Feb 2026
in Hematology
Original Research
Published on 12 Feb 2026
in Biomechanics
Original Research
Published on 12 Feb 2026
in Structural Materials
Review
Published on 12 Feb 2026
in Pharmacology of Infectious Diseases
Clinical Trial
Published on 12 Feb 2026
in Pediatric Surgery
Original Research
Published on 12 Feb 2026
in Radiation Oncology
Original Research
Published on 12 Feb 2026
in Diagnosis of Tuberculosis
Original Research
Published on 12 Feb 2026
in Neonatology
Original Research
Published on 12 Feb 2026
in Interventions for Rehabilitation
Original Research
Published on 12 Feb 2026
in Public Mental Health
Original Research
Published on 12 Feb 2026
in Orthopedic Surgery